GATA3 and urinary bladder carcinoma: Taking into consideration molecular and malignant diversity of primary and relapsed bladder cancer, the idea of our study was to analyze how PD-L1 expression associates with relapse-free survival of patients with recurrent GATA3 (+), KRT5/6 (+) and double-negative NMIBC regarding tumor grade and previous surgical and chemo-/immunotherapy settings.